GSK plc announced the completion of its $2.2 billion acquisition of RAPT Therapeutics on March 3, 2026, gaining rights to ozureprubart, a promising treatment for food allergies. The acquisition aims to improve patient outcomes, particularly for children suffering from severe food allergies.